• December 22, 2014 - N30 Pharmaceuticals Appoints Jon Congleton as President and CEO
  • November 19, 2014 - N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing
  • March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
  • October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
  • April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
  • October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Oral S-Nitrosoglutathione Reductase Inhibitor N91115: A Multiple Ascending-Dose Study In Healthy Subjects
  • October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Intravenous S-NitrosoglutathioneReductaseInhibitor N6022: An Ascending-Dose Study in Subjects Homozygous for the F508del-CFTRMutation
  • October 4, 2014 - Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro CFTR Function
  • October 4, 2014 - Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO
  • March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
More posters

November 19, 2014

N30 Pharmaceuticals Secures $30 Million in Oversubscribed Crossover Financing

Boulder, Colo., November 19, 2014 – N30 Pharmaceuticals, Inc. (“N30 Pharma”), a clinicalstage,
biopharmaceutical company focused on the development of therapies for cystic fibrosis
(CF), has raised $30 million in a mezzanine round of financing.

New investors include Wellington Management, RA Capital Management, LLC, Jennison Associates LLC (on behalf of
certain clients), Rock Springs Capital Management LP, and Sabby Management, LLC, who joined existing investor, Deerfield Management Company, LP. Cowen & Company acted as sole placement agent for the financing. More… PDF (85Kb)

Comments are closed.